Arrowhead CMO’s Zero‑Price Buy Signals Insider Confidence Amid Pipeline Boom and Capital Raise
Arrowhead’s CMO flips from selling to buying, buying 75,000 shares at a zero‑price entry, signaling renewed confidence in its RNAi obesity pipeline and upcoming capital raise.
- Arrowhead Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read